US2014011820A1PendingUtilityA1

Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Assignee: RODEMER YOLANDAPriority: Jun 1, 2006Filed: Sep 9, 2013Published: Jan 9, 2014
Est. expiryJun 1, 2026(expired)· nominal 20-yr term from priority
Inventors:Yolanda Rodemer
A61P 35/00A61P 25/04A61P 17/02A61P 17/00A61P 17/16A61K 31/519
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Use of allopurinol or a pharmaceutically acceptable salt thereof for the treatment or prevention of palmar plantar erythrodysesthesia induced by chemotherapy. The allopurinol or its salt is administered topically to the affected areas, palms and soles, preferably in the form of a cream.

Claims

exact text as granted — not AI-modified
1 - 13 . (canceled) 
     
     
         14 . A method for treating or preventing palmar plantar erythrodysesthesia (PPE) induced by fluoropyrimidine chemotherapy or by pegylated doxorubicin in a patient in need thereof comprising administering to the patient a medicament having an amount of allopurinol or a pharmaceutically acceptable salt thereof which is therapeutically effective to treat or prevent PPE. 
     
     
         15 . A pharmaceutical composition for the topical administration to the skin, comprising from 1-10% by weight of the total composition of allopurinol or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is formulated to topical administration to the skin, and is free of methylsulphonylmethane or cetomacrogol.

Join the waitlist — get patent alerts

Track US2014011820A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.